Subclinical tuberculosis among adults with HIV: clinical features and outcomes in a South African cohort

BMC Infect Dis. 2019 Jan 5;19(1):14. doi: 10.1186/s12879-018-3614-7.

Abstract

Background: Subclinical tuberculosis is an asymptomatic disease phase with important relevance to persons living with HIV. We describe the prevalence, clinical characteristics, and risk of mortality for HIV-infected adults with subclinical tuberculosis.

Methods: Untreated adults with HIV presenting for outpatient care in Durban, South Africa were screened for tuberculosis-related symptoms and had sputum tested by acid-fast bacilli smear and tuberculosis culture. Active tuberculosis and subclinical tuberculosis were defined as having any tuberculosis symptom or no tuberculosis symptoms with culture-positive sputum. We evaluated the association between tuberculosis disease category and 12-month survival using Cox regression, adjusting for age, sex, and CD4 count.

Results: Among 654 participants, 96 were diagnosed with active tuberculosis disease and 28 with subclinical disease. The median CD4 count was 68 (interquartile range 39-161) cells/mm3 in patients with active tuberculosis, 136 (72-312) cells/mm3 in patients with subclinical disease, and 249 (125-394) cells/mm3 in those without tuberculosis disease (P < 0.001). The proportion of smear positive cases did not differ significantly between the subclinical (29%) and active tuberculosis groups (14%, P 0.08). Risk of mortality was not increased in individuals with subclinical tuberculosis relative to no tuberculosis (adjusted hazard ratio 0.84, 95% confidence interval 0.26-2.73).

Conclusions: Nearly one-quarter of tuberculosis cases among HIV-infected adults were subclinical, which was characterized by an intermediate degree of immunosuppression. Although there was no significant difference in survival, anti-tuberculous treatment of subclinical cases was common.

Trial registration: Prospectively registered on ClinicalTrials.gov , NCT01188941 (August 26, 2010).

Keywords: AIDS-related opportunistic infections; Disease progression; HIV; Subclinical infections; Tuberculosis.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Anti-Retroviral Agents / therapeutic use
  • Antitubercular Agents / therapeutic use
  • Asymptomatic Infections / epidemiology*
  • Asymptomatic Infections / mortality
  • Asymptomatic Infections / therapy
  • Black People / statistics & numerical data
  • Cohort Studies
  • Female
  • Follow-Up Studies
  • HIV
  • HIV Infections / complications
  • HIV Infections / diagnosis
  • HIV Infections / drug therapy
  • HIV Infections / epidemiology*
  • Humans
  • Infection Control / methods
  • Male
  • Middle Aged
  • Prevalence
  • Prognosis
  • South Africa / epidemiology
  • Survival Analysis
  • Tuberculosis / complications
  • Tuberculosis / diagnosis
  • Tuberculosis / drug therapy
  • Tuberculosis / epidemiology*
  • Young Adult

Substances

  • Anti-Retroviral Agents
  • Antitubercular Agents

Associated data

  • ClinicalTrials.gov/NCT01188941